Yazar "Taskaynatan, Halil" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Effect of diabetes mellitus on prognosis and development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis
    (2019) Taskaynatan, Halil; Aktas, Gokmen; Vatansever, Sezgin
    Aim: Hepatitis C virus (HCV) infection and diabetes mellitus (DM) negatively affect each other. HCV patients diagnosed with DM have more complications than patients with HCV infection alone. In this study, we aimed to investigate the effect of DM on complication rate, hepatocellular cancer (HCC) development and mortality in HCV RNA (+) cirrhosis patients.Material and Methods: Patients admitted with Hepatitis C-related cirrhosis and followed up for at İzmir Katip Çelebi University Atatürk Training and Research Hospital Gastroenterology and Internal Medicine Clinic for at least six months between 2005and 2014 were retrospectively evaluated.Results: A total of 146 patients with HCV-related cirrhosis were included in the study. Of these patients, 53 (36.3%) had diagnosis of DM. In 108 patients who did not develop hepatocellular carcinoma (HCC), the mean CHILD score at final admission (p=0.024), difference between mean CHILD scores at final and initial admission (p=0.011), and annual rate of increase in CHILD score (p=0.047) was significantly higher in the DM group. There was no significant difference between the DM and non-DM groups according to both overall survival (p=0.115) and time of HCC development (p=0.567).Conclusion: While HCC development and overall survival were similar in both groups, in the subgroup of patients who did not develop HCC, the annual increase in CHILD score and final CHILD score were significantly higher in DM patients.
  • Küçük Resim
    Öğe
    Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study
    (2020) Taskaynatan, Halil; Kucukzeybek, Yuksel; Yildiz, Yasar; Salman, Tarik; Oflazoglu, Utku; Varol, Umut; Alacacioglu, Ahmet; Saray, Seray; Ozdemir, Ozlem; Tarhan, Mustafa Oktay
    Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months). Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.
  • Küçük Resim
    Öğe
    Prognostic role of pretreatment de ritis and neutrophil to lymphocyte ratio in neuroendocrine carcinoma patients (Izmir oncology group study)
    (2020) Varol, Umut; Oflazoglu, Utku; Uzum, Yusuf; Yildiz, Yasar; Salman, Tarik; Taskaynatan, Halil
    Aim: Neutrophil/lymphocyte ratio (NLR) and AST/ALT ratio (De Ritis) were found to be prognostic in several cancers. So, our aim was to investigate the prognostic importance of these parameters and clinicopathological characteristics in patients with neuroendocrine carcinoma (NEC). Material and Methods: We retrospectively reviewed 101 NEC patients diagnosed in the last decade. The values of NLR and De Ritis were assessed at the time of diagnosis and their cut-off values were determined as 5 and 1.04 by receiver operating characteristics analysis. The prognostic role of high or low NLR and De Ritis according to these cut-off values and patient or tumor characteristics on clinical outcome was evaluated. Results: Among 101 patients, 77 were metastatic and 24 were early or locally advanced stage. Almost all patients were death at the time of data analysis (n:90). Twelve patients were treated with adjuvant chemotherapy or radiotherapy while 41 metastatic patients had received first-line chemotherapy. Median overall survival (OS) and progression free survival (PFS) was 7 months and 5 months in NLR low group and 6 months and 4 months in NLR high group (p:0.043, p:0.354), respectively. Median OS was 9 months in De Ritis low group and 5 months in De Ritis high group (p:0.004) while median PFS was 5 and 4 months in De Ritis low and high group of patients (p:0.077). Conclusion: Low De Ritis showed a strong and low NLR showed a weaker association with improved prognosis in patients with NEC.